The claims administrator for the Blue Cross Blue Shield antitrust class action settlement began distributing payments to eligible claimants in May 2026, marking the first disbursements from the $2.67 billion fund [1]. Approximately 6 million claims were submitted, with average payments expected to reach around $333 per claimant [1]. The distribution represents one of the largest health insurance antitrust settlements in United States history [2].
The underlying litigation, consolidated in the Northern District of Alabama as MDL 2406, centered on allegations that Blue Cross Blue Shield Association member companies engaged in anticompetitive market allocation, specifically that member plans agreed not to compete against one another in designated geographic territories and to restrict the use of the Blue Cross Blue Shield name in competing markets [1]. Plaintiffs argued these arrangements suppressed competition in violation of the Sherman Antitrust Act, inflating premiums paid by individual and employer subscribers over an extended class period [1]. The settlement resolved claims brought by a nationwide class of subscribers without a final adjudication of liability.
The settlement fund was approved by the court following years of litigation and negotiation [2]. Eligible claimants, primarily individuals and businesses that purchased or were enrolled in Blue Cross Blue Shield health insurance plans during the class period, submitted claims through a process administered by the official settlement website [2]. Payment amounts vary based on the number of valid claims submitted and the proportion of the fund allocated to each claimant category [1].
With distribution now underway, the primary remaining procedural question is whether any appeals or residual claim disputes will affect the finality of the disbursement process [2]. The settlement administrator continues to process payments and address any outstanding claim verification issues [2]. No further substantive court proceedings are expected absent a collateral challenge.